Guardant Health, Inc.
GH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.80 | -4.15 | 0.96 | -3.75 |
| FCF Yield | -0.59% | -1.02% | -1.27% | -2.21% |
| EV / EBITDA | -103.58 | -80.64 | -70.19 | -46.29 |
| Quality | ||||
| ROIC | -9.30% | -9.29% | -9.70% | -9.83% |
| Gross Margin | 64.71% | 65.01% | 63.28% | 61.55% |
| Cash Conversion Ratio | 0.38 | 0.60 | 0.66 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.99% | 17.56% | 17.09% | 18.02% |
| Free Cash Flow Growth | 30.59% | 1.81% | 19.48% | -50.91% |
| Safety | ||||
| Net Debt / EBITDA | -8.75 | -7.94 | -7.25 | -8.17 |
| Interest Coverage | -104.97 | -108.25 | -140.38 | -195.29 |
| Efficiency | ||||
| Inventory Turnover | 1.03 | 0.97 | 0.97 | 1.09 |
| Cash Conversion Cycle | 106.88 | 94.02 | 84.16 | 86.90 |